Regeneron Pharmaceuticals Inc. faced a notable decline, dropping 1.65% in today's session.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) experienced a significant setback today, with its stock price falling by 1.65% to close at CA$814.04. This drop comes amid a broader market trend where healthcare stocks have been under pressure.
Investor takeaway: Investors should remain cautious as Regeneron navigates competitive pressures and market sentiment shifts, particularly in the biotech sector.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$80.80B
P/E
19.4x
Div. yield
0.46%
Div. / share
$3.64
52W high
$859.34
52W low
$538.24
1W change
+0.56%
Beta
0.19
Analyst Price Targets
Based on 25 analysts covering REGN · as of Sep 17, 2026
Wall Street analysts forecast REGN stock price to rise 6.4% over the next 12 months.
Consensus
Buy4.28 / 5.00
Avg. Target
C$849.32
+6.4% Upside
Current Price
C$798.17
Last close
Analyst Breakdown (25 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.0%
Annualized
90-Day Vol
29.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$954.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$847.12 | C$769.02 – C$933.16 |
| 60 trading days | C$899.08 | C$784.13 – C$1030.88 |
| 90 trading days | C$954.22 | C$807.02 – C$1128.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
-1.65%
Regeneron's stock has seen a notable drop in value, reflecting investor concerns amidst a competitive landscape.
Bull case
Despite today's decline, Regeneron has a solid lineup, including Dupixent, which continues to show strong sales growth. There’s also potential for new product developments in its pipeline that could drive future success.
Bear case
The recent decline highlights potential weaknesses in Regeneron's market position, especially with rising competition in the biotech space and the looming threat of biosimilars affecting its flagship products.
Advertisement
Market Sentiment and Performance
Regeneron's stock performance today reflects a broader trend in the healthcare sector, where investors are becoming increasingly cautious. The recent earnings report had initially boosted confidence, but the subsequent market reactions indicate that concerns over competition and pricing pressures are taking precedence. The stock's decline is a reminder of the volatility often seen in biotech stocks.
Competitive Landscape Challenges
Regeneron faces significant challenges from biosimilars and competing therapies, particularly in the lucrative markets of EYLEA and Dupixent. Although Dupixent has shown strong sales growth, the increasing number of competitors in the market could impact future revenue streams. Investors are advised to monitor these developments closely as they could influence Regeneron's market position moving forward.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
